leflunomide has been researched along with Cytomegalovirus in 22 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data concerning the use of leflunomide-a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus (CMV) activity-in lung transplant (LT) recipients are scarce." | 8.98 | Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. ( Aguado, JM; Alonso-Moralejo, R; Brañas, P; de Pablo-Gafas, A; Fernández-Ruiz, M; Folgueira, MD; Lopez-Medrano, F; Pérez-González, V; San-Juan, R; Silva, JT, 2018) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "To describe leflunomide use in the treatment of drug resistant cytomegalovirus retinitis." | 7.85 | Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis. ( Goldstein, DA; Jumroendararasame, C; Minkus, CL; Pursell, K; Rifkin, LM, 2017) |
| "Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans." | 7.81 | Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects? ( Hsieh, SC; Lu, CH; Tsai, JH; Wu, MZ; Yu, CL, 2015) |
| "The immunomodulatory drug leflunomide (LEF) is frequently used for treating human cytomegalovirus (HCMV), but its antiviral mechanism is still unclear." | 7.79 | Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. ( Hua-Song, Z; Qi, R; Xiao-Feng, Z, 2013) |
| "Leflunomide has been shown to have immunosuppressive activity in experimental allograft models together with antiviral activity inhibiting CMV both in vitro and in vivo." | 6.77 | Leflunomide for cytomegalovirus: bench to bedside. ( Chacko, B; John, GT, 2012) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 5.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 5.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "Leflunomide is a novel drug with both immunosuppressive and anti-CMV properties." | 5.33 | Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. ( Chan, LK; Levi, ME; Mandava, N; Olson, JL; Weinberg, A, 2006) |
| "Data concerning the use of leflunomide-a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus (CMV) activity-in lung transplant (LT) recipients are scarce." | 4.98 | Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. ( Aguado, JM; Alonso-Moralejo, R; Brañas, P; de Pablo-Gafas, A; Fernández-Ruiz, M; Folgueira, MD; Lopez-Medrano, F; Pérez-González, V; San-Juan, R; Silva, JT, 2018) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "To describe leflunomide use in the treatment of drug resistant cytomegalovirus retinitis." | 3.85 | Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis. ( Goldstein, DA; Jumroendararasame, C; Minkus, CL; Pursell, K; Rifkin, LM, 2017) |
| "Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans." | 3.81 | Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects? ( Hsieh, SC; Lu, CH; Tsai, JH; Wu, MZ; Yu, CL, 2015) |
| "The immunomodulatory drug leflunomide (LEF) is frequently used for treating human cytomegalovirus (HCMV), but its antiviral mechanism is still unclear." | 3.79 | Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. ( Hua-Song, Z; Qi, R; Xiao-Feng, Z, 2013) |
| "We previously reported that the immunosuppressive malononitrileamides leflunomide and FK778 exert antiviral activity against cytomegalovirus (CMV)." | 3.73 | Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. ( Chong, AS; Knight, DA; Meister, GT; Shen, J; Waldman, WJ; Williams, JW; Zeng, H, 2006) |
| "Leflunomide has been shown to have immunosuppressive activity in experimental allograft models together with antiviral activity inhibiting CMV both in vitro and in vivo." | 2.77 | Leflunomide for cytomegalovirus: bench to bedside. ( Chacko, B; John, GT, 2012) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 1.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 1.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "Leflunomide is a novel drug with both immunosuppressive and anti-CMV properties." | 1.33 | Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. ( Chan, LK; Levi, ME; Mandava, N; Olson, JL; Weinberg, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Santhanakrishnan, K | 1 |
| Yonan, N | 1 |
| Iyer, K | 1 |
| Callan, P | 1 |
| Al-Aloul, M | 1 |
| Venkateswaran, R | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Silva, JT | 1 |
| Pérez-González, V | 1 |
| Lopez-Medrano, F | 1 |
| Alonso-Moralejo, R | 1 |
| Fernández-Ruiz, M | 1 |
| San-Juan, R | 1 |
| Brañas, P | 1 |
| Folgueira, MD | 1 |
| Aguado, JM | 1 |
| de Pablo-Gafas, A | 1 |
| Dunn, JH | 1 |
| Weinberg, A | 2 |
| Chan, LK | 2 |
| Mandava, N | 2 |
| Levi, ME | 2 |
| Olson, JL | 2 |
| Verkaik, NJ | 1 |
| Hoek, RA | 1 |
| van Bergeijk, H | 1 |
| van Hal, PT | 1 |
| Schipper, ME | 1 |
| Pas, SD | 1 |
| Beersma, MF | 1 |
| Boucher, CA | 1 |
| Jedema, I | 1 |
| Falkenburg, F | 1 |
| Hoogsteden, HC | 1 |
| van den Blink, B | 1 |
| Murk, JL | 1 |
| Lu, CH | 1 |
| Tsai, JH | 1 |
| Wu, MZ | 1 |
| Yu, CL | 1 |
| Hsieh, SC | 1 |
| Boeckh, M | 1 |
| Murphy, WJ | 1 |
| Peggs, KS | 1 |
| Rifkin, LM | 1 |
| Minkus, CL | 1 |
| Pursell, K | 1 |
| Jumroendararasame, C | 1 |
| Goldstein, DA | 1 |
| Gómez Valbuena, I | 1 |
| Alioto, D | 1 |
| Serrano Garrote, O | 1 |
| Ferrari Piquero, JM | 1 |
| El Chaer, F | 1 |
| Mori, N | 1 |
| Shah, D | 1 |
| Oliver, N | 1 |
| Wang, E | 1 |
| Jan, A | 1 |
| Doan, V | 1 |
| Tverdek, F | 1 |
| Tayar, J | 1 |
| Ariza-Heredia, E | 1 |
| Chemaly, RF | 1 |
| Bright, PD | 1 |
| Gompels, M | 1 |
| Donati, M | 1 |
| Johnston, S | 1 |
| Orden, AO | 1 |
| Chuluyan, JC | 1 |
| Colombini, AC | 1 |
| Barbera, RF | 1 |
| Chacko, B | 1 |
| John, GT | 1 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Carmichael, A | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Qi, R | 1 |
| Hua-Song, Z | 1 |
| Xiao-Feng, Z | 1 |
| Evers, DL | 1 |
| Wang, X | 1 |
| Huong, SM | 1 |
| Andreoni, KA | 1 |
| Huang, ES | 1 |
| Chong, AS | 3 |
| Zeng, H | 1 |
| Knight, DA | 3 |
| Shen, J | 2 |
| Meister, GT | 1 |
| Williams, JW | 3 |
| Waldman, WJ | 3 |
| Battiwalla, M | 1 |
| Paplham, P | 1 |
| Almyroudis, NG | 1 |
| McCarthy, A | 1 |
| Abdelhalim, A | 1 |
| Elefante, A | 1 |
| Smith, P | 1 |
| Becker, J | 1 |
| McCarthy, PL | 1 |
| Segal, BH | 1 |
| Mossad, SB | 1 |
| Avery, RK | 1 |
| Lurain, NS | 2 |
| Miller, DM | 2 |
| Sedmak, DD | 2 |
| Blinder, L | 1 |
5 reviews available for leflunomide and Cytomegalovirus
| Article | Year |
|---|---|
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; | 2022 |
Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
Topics: Adult; Aged; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Humans; Immunos | 2018 |
Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, | 2013 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Thera | 2015 |
Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Blood; Cytomegalovirus; Cytomegalovirus Infe | 2017 |
1 trial available for leflunomide and Cytomegalovirus
| Article | Year |
|---|---|
Leflunomide for cytomegalovirus: bench to bedside.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Isoxazoles; Leflunomide; Tran | 2012 |
16 other studies available for leflunomide and Cytomegalovirus
| Article | Year |
|---|---|
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
Topics: Administration, Oral; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resi | 2013 |
Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects?
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dr | 2015 |
Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
Topics: Administration, Oral; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resis | 2017 |
[Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Human | 2016 |
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
Topics: Aged; Antiviral Agents; Chemotherapy, Adjuvant; Cytomegalovirus; Cytomegalovirus Infections; Drug Mo | 2016 |
Leflunomide use in a cytomegalovirus infection of a patient with dermatomyositis.
Topics: Antirheumatic Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dermatomyositis | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus.
Topics: Apoptosis; Cell Proliferation; Cell Shape; Cytomegalovirus; Cytomegalovirus Infections; Embryo, Mamm | 2013 |
Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778.
Topics: Alkynes; Antiviral Agents; Cell Line; Cytomegalovirus; Humans; Immunosuppressive Agents; Isoxazoles; | 2005 |
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft Rejection; Heart; Hear | 2006 |
Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Multiple, Vira | 2006 |
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Therapy, Co | 2007 |
Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Isoxazoles; Leflunomide; Rena | 2007 |
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
Topics: Antiviral Agents; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA | 1999 |
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; | 1999 |